Drugs / FT596
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05934097 | Dec 2022 → May 2026 | diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma | Fate Therapeutics | Withdrawn | No outcome recorded Stop: Business |
| Phase 1 | NCT04555811 | Sep 2020 → Feb 2023 | high grade B-cell lymphoma | Masonic Cancer Center, University of Minnesota | Completed | No outcome recorded |
| Phase 1 | NCT04245722 | Mar 2020 → Sep 2023 | B-cell chronic lymphocytic leukemia | Fate Therapeutics | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 12
| Date | Issuer | Release |
|---|---|---|
| 2025-03-01 | Hopstem Biotechnology Inc. | Results 2025【二月精选】领域最新进展 hopstem.com ↗
值得注意的是，未观察到神经毒性。 |
| 2024-11-18 | Fate Therapeutics | Results Fate Therapeutics Highlights FT522 Off-the-shelf, ADR-armed CAR NK Cell Product Candidate at 2024 ACR Convergence fatetherapeutics.com ↗
FT596 demonstrated a favorable safety profile, with no events of ICANS or GvHD and low incidence of low grade CRS (Grade 1 = 10%; Grade 2 = 4%; Grade ≥3 = 0). |
| 2021-12-13 | Fate Therapeutics | Results Fate Therapeutics Showcases Positive Interim Phase 1 Data from FT596 Off-the-shelf, iPSC-derived CAR NK Cell Program for Relapsed / Refractory B-cell Lymphoma at 2021 ASH Annual Meeting fatetherapeutics.com ↗
today showcased positive interim Phase 1 data from the Company’s FT596 program for patients with relapsed / refractory B-cell lymphoma (BCL) at the 63 rd American Society of Hematology (ASH) Annual Meeting and Exposition. |
| 2021-08-19 | Fate Therapeutics | Results Fate Therapeutics Announces Positive Interim Clinical Data from its FT596 and FT516 Off-the-shelf, iPSC-derived NK Cell Programs for B-cell Lymphoma fatetherapeutics.com ↗
Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer, today highlighted positive interim clinical data from the Company’s FT516 and FT596 programs for patients with relapsed / refractory B-cell lymphoma. |
| 2021-05-05 | Fate Therapeutics | Regulatory Fate Therapeutics Reports First Quarter 2021 Financial Results and Highlights Operational Progress fatetherapeutics.com ↗
The Company has submitted a protocol amendment to the U.S. Food and Drug Administration (FDA) to also assess administration of multi-dose treatment schedules for FT596. |
| 2020-12-06 | Fate Therapeutics | Results Fate Therapeutics Presents Patient Case Study Demonstrating Clinical Activity of FT596 in Refractory Diffuse Large B-cell Lymphoma fatetherapeutics.com ↗
The case study described a heavily pre-treated patient with diffuse large B-cell lymphoma (DLBCL) who achieved a partial response following administration of a single-dose treatment cycle of FT596 as a monotherapy in the first dose cohort of 30 million cells. |
| 2020-08-05 | Fate Therapeutics | Results Fate Therapeutics Reports Second Quarter 2020 Financial Results and Highlights Operational Progress fatetherapeutics.com ↗
Early clinical data from our FT596 program are very encouraging, as we observed a partial response in a heavily-pretreated patient with refractory diffuse large B-cell lymphoma at the first dose level without any reported events of cytokine release syndrome, neurotoxicity or graft-versus-host disease. |
| 2020-05-11 | Fate Therapeutics | Regulatory Fate Therapeutics Reports First Quarter 2020 Financial Results and Highlights Operational Progress fatetherapeutics.com ↗
Second FT596 IND Allowed by FDA for Relapse Prevention after Autologous HSCT for Non-Hodgkin Lymphoma |
| 2019-12-08 | Fate Therapeutics | Results Fate Therapeutics Announces New Preclinical Data for FT596 Off-the-Shelf, iPSC-derived CAR NK Cell Cancer Immunotherapy fatetherapeutics.com ↗
Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced new in vivo preclinical data for FT596, its off-the-shelf, multi-antigen targeting natural killer (NK) cell product candidate derived from a clonal master engineered induced pluripotent stem cell (iPSC) line. |
| 2019-11-05 | Fate Therapeutics | Regulatory Fate Therapeutics Reports Third Quarter 2019 Financial Results and Highlights Operational Progress fatetherapeutics.com ↗
The FDA has allowed investigation of FT596 in an open-label Phase 1 clinical trial as a monotherapy, in combination with rituximab for the treatment of advanced B-cell lymphoma, and in combination with obinutuzumab for the treatment of chronic lymphocytic leukemia. |
| 2019-09-03 | Fate Therapeutics | Regulatory Fate Therapeutics Announces FDA Clearance of IND Application for FT596 Off-the-Shelf, iPSC-derived CAR NK Cell Cancer Immunotherapy fatetherapeutics.com ↗ |
| 2018-12-04 | Fate Therapeutics | Results Fate Therapeutics Presents Off-the-Shelf CAR T and NK Cell Cancer Immunotherapy Pipeline at ASH Annual Meeting fatetherapeutics.com ↗
A poster presentation at ASH by scientists from the Company and the University of California – San Diego highlighted new in vivo data demonstrating that FT596 displays long-term persistence without systemic cytokine support. |
All press releases naming this drug 13 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FT596 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04245722 ↗ |
| Modality | Cell therapy | “FT596 is an induced pluripotent stem-cell (iPSC)-derived chimeric antigen receptor (CAR) natural killer (NK) cell therapy” PMID 39798981 ↗ Jan 2025 |
| Route | Intravenous | “Dosing to be initiated at a dose no higher than highest tolerable dose in study FT596-101, intravenously” NCT05934097 ↗ |
| Target | CD19 | “a CD19 CAR” PMID 39798981 ↗ Jan 2025 |